Related Articles
Clinical activity of crizotinib in lung adenocarcinoma harboring a <em>HLA_A</em>‑<em>ROS1</em> rearrangement: A case report
ROS1‑rearranged high‑PD‑L1‑expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report
Clinicopathological features and clinical efficacy of crizotinib in Chinese patients with ROS1‑positive non‑small cell lung cancer
ALK inhibitors and advanced non-small cell lung cancer (Review)
Quantitative volumetric assessment of the solid portion percentage on CT images to predict ROS1/ALK rearrangements in lung adenocarcinomas